pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Incidence of all-grade treatment-related adverse events in nivolumab and pembrolizumab groups

Adverse events* Nivolumab (n=48) Pembrolizumab (n=19)

n (%) n (%)
Any 48 (100) 19 (100)
Pneumonia 10 (20.8) 1 (5.3)
Fatigue 24 (50.0) 8 (42.1)
Anorexia 24 (50.0) 10 (52.6)
Weakness 25 (52.1) 3 (15.8)
Respiratory diseases 34 (70.8) 10 (52.6)
Nausea and vomiting 15 (31.3) 6 (31.6)
Immune related diseases 33 (68.8) 14 (73.7)
Thyroidal diseases 10 (20.8) 0 (0.0)
Pain 34 (70.8) 13 (68.4)
GI tract diseases 42 (87.5) 18 (94.7)
Hematologic toxicity 22 (45.8) 6 (31.6)
Infusion related responses 19 (39.6) 2 (10.5)
Neuropathy 11 (22.9) 6 (31.6)
Fever 16 (33.3) 1 (5.3)

*National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0

All adverse symptoms were recorded from 67 patients and grouped into each treatment.

Korean J Clin Pharm 2020;30:11-8 https://doi.org/10.24304/kjcp.2020.30.1.11
© 2020 Korean J Clin Pharm